bioMérieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMérieux‘s molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient.
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2013.
With this acquisition, bioMérieux consolidates its position as a major player in infectious disease diagnostics and strengthens its presence in the United States.
VITEK® MS MALDI-TOF system reduces the time to detect microbial contaminants from days to minutes, adding a never-before possible level of safety in the production of many consumer goods.
bioMérieux, a world leader in the field of in vitro diagnostics, has announced that it is moving a new step forward to its comprehensive automation solution dedicated for reference or centralized molecular biology laboratories.
Please be advised of the updated 2013 holiday shipping schedule as we enter the Thanksgiving and Christmas seasons.
With the acquisition of BioFire, bioMérieux consolidates its position as a major player in infectious disease diagnostics.
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on August 30 to approve the consolidated financial statements for the six months ended June 30, 2013.
New Technology made possible by a Nobel Prize Winning discovery holds the promise to improve clinical decision-making for infectious diseases.
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended June 30, 2013.
